重组人促红素联合硼替佐米和地塞米松治疗老年多发性骨髓瘤疗效评价

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (629 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Recombinant Human Erythropoietin combined with Bortezomib and Dexamethasone in the treatment of elderly patients with multiple myeloma，in order to find a safe and efficient treatment plan for elderly patients with multiple myeloma. Methods A total of 80 elderly patients with multiple myeloma admitted to Wuming Hospital Affiliated to Guangxi Medical University from January 2016 to April 2021 were selected as the research subjects，and were divided into study group (40 cases) and control group (40 cases) according to random number table method. The control group was treated with Bortezomib combined with Dexamethasone，and the study group was treated with Recombinant Human Erythropoietin and Bortezomib combined with Dexamethasone. The total effective rate，laboratory indicators and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the study group was 85.0%，higher than that of the control group (72.5%)，and the difference was statistically significant (P＜0.05). After treatment，hemoglobin and albumin in the study group were higher than those in the control group，while creatinine，β2 microglobulin and serum calcium were lower than those in the control group，the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of Recombinant Human Erythropoietin，Bortezomib and Dexamethasone for multiple myeloma patients can achieve good curative effect，improve the blood index，and have good safety，which is worthy of clinical application and promotion.

Key words： Recombinant Human Erythropoietin Bortezomib Dexamethasone Multiple myeloma

Received: 15 July 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2022/V29/I1/39

[1]	蔡小平，石岳坚，郑翠苹，等.血清血小板因子4 对采用沙利度胺联合VCD 治疗的新发多发性骨髓瘤患者疗效的预测价值[J].中华全科医学，2019，17（12）：2035-2037，2078.
[2]	杨云，马圣宇.硼替佐米对多发性骨髓瘤患者联合化疗安全性及预后的影响[J].中华保健医学杂志，2019，21（3）：279-281.
[3]	苑冬阳，廖爱军.老年多发性骨髓瘤治疗研究进展[J].中华实用诊断与治疗杂志，2019，33（4）：403-405.
[4]	张丽，罗文达，沈健，等.含硼替佐米的联合化疗对多发性骨髓瘤的治疗效果及不良反应[J].中华全科医学，2016，14（11）：1826-1828.
[5]	中华医师协会血液科医师分会，中华医学会血液学分会，中华医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南（2017年修订）[J].中华内科杂志，2017，56（11）：866-870.
[6]	Trotti A，Colevas AD，Setser A，et al.CTCAE v3.0：development of a comprehensive grading system for the adverseeffects of cancer treatment[J].Semin Radiat Oncol，2003，13（3）：176-181.
[7]	Salvini M，D′agostino M，Bonello F，et al.Determining treatment intensity in elderly patients with multiple myeloma[J].Expert Rev Anticancer Ther，2018，18（9）：917-930.
[8]	Atamaniuk J，Gleiss A，Porpaczy E，et al.Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma[J].Eur J Clin Invest，42（9）：953-960.
[9]	Moehler T，Goldschmidt H.Therapy of relapsed and refractory multiple myeloma[J].Recent Results Cancer Res，2011，183：239-271.
[10]	Boles KS，Mathew PA.Molecular cloning of CS1，a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily[J].Immunogenetics，2001，52（3-4）：302-307.
[11]	Brentjens R，Yeh R，Bernal Y，et al.Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells：case report of an unforeseen adverse event in a phase I clinical trial[J].Mol Ther，2010，18（4）：666-668.
[12]	Brudno JN，Kochenderfer JN.Toxicities of chimeric antigen receptor T cells：recognition and management [J].Blood，2016，127（26）：3321-3330.
[13]	Carpenter RO，Evbuomwan MO，Pittaluga S，et al.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma[J].Clin Cancer Res，2013，19（8）：2048-2060.
[14]	Chekmasova AA，Horton HM，Garrett TE，et al.A novel and highly potent CAR T cell drug product for treatment of BCMA-expressing hematological malignances[J].Blood，2015，126（23）：3094.
[15]	Gogishvili T，Danhof S，Prommersberger S，et al.SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+normal lymphocytes[J].Blood，2017，130（26）：2838-2847.
[16]	Cohen Y，Gutwein O，Garach-Jehoshua O，et al.GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells[J].Hematology，2013，18（6）：348-351.
[17]	Cremer FW，Bila J，Buck I，et al.Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics[J].Genes Chromosomes Cancer，2005，44（2）：194-203.
[18]	Davila ML，Riviere I，Wang XY，et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in Bcell acute lymphoblastic leukemia[J].Sci Transl Med，2014，6（6）：675-678.
[19]	Drent E，Groen RWJ，Noort WA，et al.Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma[J].Haematologica，2016，101（5）：616-625.
[20]	Gauthier J，Turtle CJ.Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-Tcell therapy[J].Curr Res Transl Med，2018，66（2）：50-52.